File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Viral hepatitis C

TitleViral hepatitis C
Authors
Issue Date2003
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet
Citation
Lancet, 2003, v. 362 n. 9401, p. 2095-2100 How to Cite?
AbstractMore than 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), which is responsible for more than 100 000 cases of liver cancer per year, with similar numbers of digestive haemorrhage and ascites episodes. Major breakthroughs have been made in diagnosis and treatment, and advances in molecular biology mean that the replicative state of the virus can now be assessed. Genotype and serum viral load are useful predictors of response to treatment. The combination of pegylated interferon and ribavirin can eradicate the virus in more than 50% of patients. These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment.
Persistent Identifierhttp://hdl.handle.net/10722/76969
ISSN
2015 Impact Factor: 44.002
2015 SCImago Journal Rankings: 14.638
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPoynard, Ten_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorRatziu, Ven_HK
dc.contributor.authorLung Lai, Cen_HK
dc.date.accessioned2010-09-06T07:26:52Z-
dc.date.available2010-09-06T07:26:52Z-
dc.date.issued2003en_HK
dc.identifier.citationLancet, 2003, v. 362 n. 9401, p. 2095-2100en_HK
dc.identifier.issn0140-6736en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76969-
dc.description.abstractMore than 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), which is responsible for more than 100 000 cases of liver cancer per year, with similar numbers of digestive haemorrhage and ascites episodes. Major breakthroughs have been made in diagnosis and treatment, and advances in molecular biology mean that the replicative state of the virus can now be assessed. Genotype and serum viral load are useful predictors of response to treatment. The combination of pegylated interferon and ribavirin can eradicate the virus in more than 50% of patients. These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment.en_HK
dc.languageengen_HK
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lanceten_HK
dc.relation.ispartofLanceten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntiviral Agents - pharmacology - therapeutic useen_HK
dc.subject.meshComorbidityen_HK
dc.subject.meshDisease Progressionen_HK
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_HK
dc.subject.meshGenotypeen_HK
dc.subject.meshHIV Infections - drug therapy - epidemiologyen_HK
dc.subject.meshHepacivirus - drug effects - genetics - isolation & purificationen_HK
dc.subject.meshHepatitis C - diagnosis - drug therapy - epidemiologyen_HK
dc.subject.meshHepatitis C, Chronic - diagnosis - drug therapy - epidemiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInterferon-alpha - pharmacology - therapeutic useen_HK
dc.subject.meshInterferons - pharmacology - therapeutic useen_HK
dc.subject.meshLiver Cirrhosis - diagnosis - pathologyen_HK
dc.subject.meshPolyethylene Glycols - pharmacology - therapeutic useen_HK
dc.subject.meshRNA, Viral - analysis - genetics - immunologyen_HK
dc.subject.meshRecombinant Proteinsen_HK
dc.subject.meshRibavirin - pharmacology - therapeutic useen_HK
dc.subject.meshSerotypingen_HK
dc.subject.meshSeverity of Illness Indexen_HK
dc.titleViral hepatitis Cen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0140-6736&volume=362&spage=2095&epage=2100&date=2003&atitle=Viral+Hepatitis+Cen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0140-6736(03)15109-4en_HK
dc.identifier.pmid14697814-
dc.identifier.scopuseid_2-s2.0-0346157289en_HK
dc.identifier.hkuros87522en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0346157289&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume362en_HK
dc.identifier.issue9401en_HK
dc.identifier.spage2095en_HK
dc.identifier.epage2100en_HK
dc.identifier.isiWOS:000187429600028-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridPoynard, T=7103155394en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridRatziu, V=7004350599en_HK
dc.identifier.scopusauthoridLung Lai, C=6504338506en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats